Vasopressin antagonists in heart failure.

Ladan Golestaneh, Ashok Talreja, Thierry H. Le Jemtel

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

The recrudescence of interest in manipulation of the arginine vasopressin system and especially of V2 vasopressin receptor blockade in heart failure stems from the limited efficacy and possible detrimental effects of loop diuretics. The "braking phenomenon," hypertrophy of the collecting duct cells, and altered pharmacodynamics contribute to loop diuretic resistance in heart failure. Selective (tolvaptan) and nonselective (conivaptan) V2 vasopressin receptor antagonists now known as "vaptans" promote free-water excretion that is labeled aquaresis and correct hyponatremia in patients with severe heart failure. A large mortality study with tolvaptan in heart failure is presently ongoing.

Original languageEnglish (US)
Pages (from-to)190-196
Number of pages7
JournalCurrent heart failure reports
Volume1
Issue number4
DOIs
StatePublished - Dec 2004

    Fingerprint

ASJC Scopus subject areas

  • Emergency Medicine
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this